2-[(1-benzyl-5-bromo-1H-indazol-3-yl)methoxy]-2-methylpropanoic acid | 1186507-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-[(1-benzyl-5-bromo-1H-indazol-3-yl)methoxy]-2-methylpropanoic acid
• 英文别名: 2-[(1-Benzyl-5-bromoindazol-3-yl)methoxy]-2-methylpropanoic acid
• CAS: 1186507-66-3
• 化学式: C₁₉H₁₉BrN₂O₃
• 分子量: 403.275
• InChiKey: XHMPKWZWVAPUSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  宾达利 在 溴 、 溶剂黄146 作用下， 生成 2-[(1-benzyl-5-bromo-1H-indazol-3-yl)methoxy]-2-methylpropanoic acid
  参考文献：
  名称：

  [EN] 1-BENZYL-3-HYDROXYMETHYLINDAZOI?E DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
  [FR] NOUVEAUX DÉRIVÉS DE 1-BENZYL-3-HYDROXYMÉTHYLINDAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES BASÉES SUR L'EXPRESSION DE MCP-1, CX3CR1 ET P40

  摘要：

  公开号：

  WO2009109613A3

文献信息

• NOVEL 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40
  申请人：Guglielmotti Angelo

  公开号：US20110003874A1

  公开（公告）日：2011-01-06

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及根据权利要求中所述公式（I）描述的新型1-苄基-3-羟甲基吲唑衍生物，以及包含它们的药物组合物和药学上可接受的载体。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备用于治疗基于MCP-1、CX3CR1和p40表达的疾病的药物组合物，并将它们用于治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法。
• 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP3181551A1

  公开（公告）日：2017-06-21

  The present invention relates to 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle, for use in the treatment of diseases based on the expression of CX3CR1 and p40.

  本发明涉及权利要求中所述的式(I)的1-苄基-3-羟甲基吲唑衍生物，以及由它们和药学上可接受的载体组成的药物组合物，用于治疗基于CX3CR1和p40表达的疾病。
• 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP2254869A2

  公开（公告）日：2010-12-01
• NEUE 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 UND P40
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP2254869B1

  公开（公告）日：2017-05-31
• US8835481B2
  申请人：——

  公开号：US8835481B2

  公开（公告）日：2014-09-16